POTENTIAL TARGETS FROM HUMAN (RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES)
1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		1soj CGMP-INHIBITED
3',5'-CYCLIC
PHOSPHODIESTERASE B
(Homo
sapiens)		8 / 12TYR A 736
HIS A 737
LEU A 895
ILE A 955
GLU A 958
PHE A 959
GLN A 988
PHE A 991
IBM  A2111 (-4.5A)
IBM  A2111 ( 4.8A)
None
IBM  A2111 (-4.2A)
None
None
IBM  A2111 (-3.3A)
IBM  A2111 (-3.6A)
0.59A24.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		1u0n PLATELET
GLYCOPROTEIN IB
(Homo
sapiens)		5 / 12TYR D 215
LEU D 197
LEU D 168
ILE D 187
PHE D 216
None
1.25A22.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		1x5c PROTEIN
DISULFIDE-ISOMERASE
(Homo
sapiens)		5 / 12LEU A  43
LEU A  83
ILE A  62
TYR A  54
PHE A 106
None
1.10A15.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		1zkl HIGH-AFFINITY
CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 7A
(Homo
sapiens)		6 / 12TYR A 211
HIS A 212
GLU A 383
PHE A 384
GLN A 413
PHE A 416
IBM  A 503 (-4.6A)
None
None
IBM  A 503 (-4.5A)
IBM  A 503 (-3.0A)
IBM  A 503 (-3.4A)
0.74A28.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		2qyk CYCLIC AMP-SPECIFIC
PHOSPHODIESTERASE
HSPDE4A10
(Homo
sapiens)		9 / 12TYR A 371
HIS A 372
LEU A 531
ILE A 548
GLU A 551
PHE A 552
MET A 569
GLN A 581
PHE A 584
NPV  A   3 (-4.4A)
NPV  A   3 (-4.6A)
None
NPV  A   3 (-3.8A)
None
NPV  A   3 (-4.8A)
NPV  A   3 (-3.1A)
NPV  A   3 (-3.1A)
NPV  A   3 (-3.3A)
1.00A29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		2qym PHOSPHODIESTERASE 4C
(Homo
sapiens)		6 / 12TYR A 281
HIS A 282
LEU A 441
ILE A 458
GLU A 461
PHE A 494
None
1.07A28.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		2qym PHOSPHODIESTERASE 4C
(Homo
sapiens)		6 / 12TYR A 281
HIS A 282
LEU A 441
ILE A 458
GLU A 461
PHE A 494
None
1.41A28.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3b2r CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		8 / 12TYR A 612
HIS A 613
LEU A 725
LEU A 765
GLU A 785
PHE A 786
GLN A 817
PHE A 820
VDN  A   1 (-4.8A)
VDN  A   1 (-4.3A)
None
VDN  A   1 ( 4.7A)
None
None
VDN  A   1 (-3.0A)
VDN  A   1 (-3.6A)
0.81A38.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3bjc CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		8 / 12TYR A 612
HIS A 613
LEU A 725
LEU A 765
GLU A 785
PHE A 786
GLN A 817
PHE A 820
None
MG  A 877 (-4.4A)
None
WAN  A 901 ( 4.7A)
None
WAN  A 901 (-4.8A)
WAN  A 901 (-3.1A)
WAN  A 901 (-3.7A)
0.82A19.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3ecn HIGH AFFINITY
CAMP-SPECIFIC AND
IBMX-INSENSITIVE
3',5'-CYCLIC
PHOSPHODIESTERASE 8A
(Homo
sapiens)		6 / 12TYR A 555
HIS A 556
ILE A 744
GLU A 747
GLN A 778
PHE A 781
None
None
IBM  A   3 (-4.3A)
None
IBM  A   3 (-3.4A)
IBM  A   3 (-3.5A)
0.92A24.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3g4g CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		6 / 12TYR A 325
HIS A 326
LEU A 485
GLU A 505
PHE A 506
PHE A 201
None
D71  A 901 (-4.5A)
None
None
D71  A 901 (-4.8A)
D71  A 901 (-4.9A)
1.35A25.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3g4g CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		8 / 12TYR A 325
HIS A 326
LEU A 485
ILE A 502
GLU A 505
PHE A 506
GLN A 535
PHE A 538
None
D71  A 901 (-4.5A)
None
D71  A 901 (-4.1A)
None
D71  A 901 (-4.8A)
D71  A 901 (-3.1A)
D71  A 901 (-3.9A)
0.92A25.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3g4g CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		6 / 12TYR A 325
HIS A 326
LEU A 485
ILE A 502
GLU A 505
PHE A 538
None
D71  A 901 (-4.5A)
None
D71  A 901 (-4.1A)
None
D71  A 901 (-3.9A)
1.49A25.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3ibj CGMP-DEPENDENT
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		8 / 12HIS A 656
LEU A 770
LEU A 809
ILE A 826
TYR A 827
GLU A 829
GLN A 859
PHE A 862
None
0.77A21.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3ibj CGMP-DEPENDENT
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		8 / 12TYR A 655
HIS A 656
LEU A 809
ILE A 826
TYR A 827
GLU A 829
GLN A 859
PHE A 862
None
0.72A21.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3o57 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		8 / 12TYR A 233
HIS A 234
LEU A 393
ILE A 410
GLU A 413
PHE A 414
GLN A 443
PHE A 446
None
None
None
ZG2  A 506 (-4.4A)
None
ZG2  A 506 (-4.4A)
ZG2  A 506 (-3.3A)
ZG2  A 506 (-3.6A)
0.87A27.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3rjo ENDOPLASMIC
RETICULUM
AMINOPEPTIDASE 1
(Homo
sapiens)		5 / 12LEU A 591
LEU A 589
ILE A 535
TYR A 612
PHE A 569
None
1.16A22.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		8 / 12TYR A 159
HIS A 160
LEU A 319
ILE A 336
GLU A 339
MET A 357
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
LEU  A 319 ( 0.6A)
ILE  A 336 ( 0.4A)
GLU  A 339 ( 0.5A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
1.01A27.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		8 / 12TYR A 159
HIS A 160
LEU A 319
ILE A 336
GLU A 339
PHE A 340
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
HIS  A 160 ( 1.0A)
LEU  A 319 ( 0.6A)
ILE  A 336 ( 0.4A)
GLU  A 339 ( 0.5A)
PHE  A 340 (-1.3A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.83A27.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3uem PROTEIN
DISULFIDE-ISOMERASE
(Homo
sapiens)		5 / 12LEU A 403
LEU A 443
ILE A 422
TYR A 414
PHE A 466
None
1.10A21.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3ui7 CAMP AND
CAMP-INHIBITED CGMP
3',5'-CYCLIC
PHOSPHODIESTERASE
10A
(Homo
sapiens)		12 / 12TYR A 524
HIS A 525
LEU A 635
LEU A 675
VAL A 678
ILE A 692
TYR A 693
GLU A 695
PHE A 696
MET A 713
GLN A 726
PHE A 729
C1L  A   1 ( 4.8A)
C1L  A   1 (-4.1A)
None
C1L  A   1 (-4.3A)
C1L  A   1 (-4.9A)
C1L  A   1 (-4.3A)
None
None
C1L  A   1 ( 4.7A)
C1L  A   1 (-3.7A)
C1L  A   1 (-2.9A)
C1L  A   1 (-3.5A)
0.54A100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3v98 ARACHIDONATE
5-LIPOXYGENASE
(Homo
sapiens)		5 / 12LEU A 443
LEU A 448
VAL A 541
GLU A 376
PHE A 525
None
1.02A17.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4a6e HYDROXYINDOLE
O-METHYLTRANSFERASE
(Homo
sapiens)		5 / 12TYR A 147
LEU A 160
ILE A 146
TYR A 131
GLN A 306
SAM  A1349 (-4.7A)
SAM  A1349 (-4.1A)
None
None
ASE  A1350 (-3.4A)
1.23A22.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4el1 PROTEIN
DISULFIDE-ISOMERASE
(Homo
sapiens)		5 / 12LEU A 403
LEU A 443
ILE A 422
TYR A 414
PHE A 466
None
1.14A22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4htz CGMP-DEPENDENT
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		11 / 12TYR A 655
HIS A 656
LEU A 770
LEU A 809
ILE A 826
TYR A 827
GLU A 829
PHE A 830
MET A 847
GLN A 859
PHE A 862
None
0.65A35.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4ric FANCONI-ASSOCIATED
NUCLEASE 1
(Homo
sapiens)		5 / 12LEU A 935
LEU A 973
ILE A 831
PHE A 922
PHE A 838
None
0.96A20.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4u2n ZINC FINGER AND BTB
DOMAIN-CONTAINING
PROTEIN 17,NUCLEUS
ACCUMBENS-ASSOCIATED
PROTEIN 1
(Homo
sapiens)		5 / 12HIS A   6
LEU A 174
ILE A 235
GLU A 237
PHE A 204
None
1.20A21.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4wzi CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		8 / 12TYR A 405
HIS A 406
LEU A 565
ILE A 582
GLU A 585
PHE A 586
GLN A 615
PHE A 618
None
MG  A 804 ( 4.9A)
None
None
None
None
None
None
0.83A20.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4x4w CCA TRNA
NUCLEOTIDYLTRANSFERA
SE 1, MITOCHONDRIAL
(Homo
sapiens)		5 / 12LEU A 235
VAL A 237
ILE A 165
PHE A 157
PHE A 176
None
1.17A20.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		5b25 CALCIUM/CALMODULIN-D
EPENDENT
3',5'-CYCLIC
NUCLEOTIDE
PHOSPHODIESTERASE 1B
(Homo
sapiens)		6 / 12TYR A 222
HIS A 223
GLU A 391
PHE A 392
GLN A 421
PHE A 424
None
4QJ  A 603 ( 4.9A)
None
GOL  A 607 (-3.9A)
4QJ  A 603 (-3.0A)
4QJ  A 603 (-3.5A)
0.84A25.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		5ddb MENIN
(Homo
sapiens)		5 / 12LEU A  41
LEU A 263
ILE A  16
GLU A 255
PHE A  78
None
1.06A23.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		5ohj CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		9 / 12TYR A 405
HIS A 406
LEU A 565
ILE A 582
GLU A 585
PHE A 586
MET A 603
GLN A 615
PHE A 618
None
None
9VE  A 801 (-4.7A)
9VE  A 801 (-4.1A)
None
9VE  A 801 (-3.6A)
9VE  A 801 (-3.6A)
9VE  A 801 (-3.2A)
9VE  A 801 (-3.9A)
1.04A11.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		5txk UBIQUITIN
CARBOXYL-TERMINAL
HYDROLASE
35,UBIQUITIN
CARBOXYL-TERMINAL
HYDROLASE 35
(Homo
sapiens)		5 / 12TYR A 524
LEU A 532
LEU A 484
ILE A 455
PHE A 465
None
1.28A13.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		5ums FACT COMPLEX SUBUNIT
SSRP1
(Homo
sapiens)		5 / 12LEU A 352
VAL A 418
ILE A 374
GLU A 373
PHE A 391
None
1.15A13.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		5wh6 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		9 / 12TYR A 159
HIS A 160
LEU A 319
ILE A 336
GLU A 339
PHE A 340
MET A 357
GLN A 369
PHE A 372
AKJ  A 601 ( 4.7A)
None
AKJ  A 601 ( 4.6A)
AKJ  A 601 (-3.8A)
None
AKJ  A 601 (-4.5A)
AKJ  A 601 (-3.4A)
AKJ  A 601 (-3.0A)
AKJ  A 601 (-4.1A)
1.07Aundetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_A_EV1A1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		6eoq DIPEPTIDYL PEPTIDASE
9
(Homo
sapiens)		5 / 12LEU A 338
LEU A 381
VAL A 379
ILE A 352
PHE A 346
None
1.26A14.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		1bnl COLLAGEN XVIII
(Homo
sapiens)		4 / 8LEU A  86
VAL A 119
ILE A 100
PHE A  49
None
0.83A16.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		1dbh PROTEIN (HUMAN SOS
1)
(Homo
sapiens)		4 / 8LEU A 324
ILE A 245
PHE A 246
PHE A 237
None
0.97A21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		1soj CGMP-INHIBITED
3',5'-CYCLIC
PHOSPHODIESTERASE B
(Homo
sapiens)		5 / 8LEU A 895
ILE A 955
PHE A 959
GLN A 988
PHE A 991
None
IBM  A2111 (-4.2A)
None
IBM  A2111 (-3.3A)
IBM  A2111 (-3.6A)
0.35A24.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		1xdv SON OF SEVENLESS
PROTEIN HOMOLOG 1
(Homo
sapiens)		4 / 8LEU A 324
ILE A 245
PHE A 246
PHE A 237
None
0.98A16.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		2qqm NEUROPILIN-1
(Homo
sapiens)		4 / 8LEU A 551
VAL A 495
ILE A 517
PHE A 515
None
0.98A19.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		2qyk CYCLIC AMP-SPECIFIC
PHOSPHODIESTERASE
HSPDE4A10
(Homo
sapiens)		5 / 8ILE A 548
PHE A 552
MET A 569
GLN A 581
PHE A 584
NPV  A   3 (-3.8A)
NPV  A   3 (-4.8A)
NPV  A   3 (-3.1A)
NPV  A   3 (-3.1A)
NPV  A   3 (-3.3A)
0.87A29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		2yd0 ENDOPLASMIC
RETICULUM
AMINOPEPTIDASE 1
(Homo
sapiens)		4 / 8LEU A 591
ILE A 535
TYR A 612
PHE A 569
None
0.96A17.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		2z13 EF-HAND
DOMAIN-CONTAINING
FAMILY MEMBER C2
(Homo
sapiens)		4 / 8VAL A  52
ILE A  73
TYR A  84
PHE A 102
None
0.94A15.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		2z7x TOLL-LIKE RECEPTOR
2, VARIABLE
LYMPHOCYTE RECEPTOR
B
(Eptatretus
burgeri;
Homo
sapiens)		4 / 8LEU A 498
VAL A 464
ILE A 455
PHE A 472
None
0.92A20.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3b2r CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		4 / 8LEU A 725
PHE A 786
GLN A 817
PHE A 820
None
None
VDN  A   1 (-3.0A)
VDN  A   1 (-3.6A)
0.52A38.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3bjc CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		4 / 8LEU A 725
PHE A 786
GLN A 817
PHE A 820
None
WAN  A 901 (-4.8A)
WAN  A 901 (-3.1A)
WAN  A 901 (-3.7A)
0.39A19.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3g4g CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		4 / 8ILE A 502
PHE A 506
GLN A 535
PHE A 538
D71  A 901 (-4.1A)
D71  A 901 (-4.8A)
D71  A 901 (-3.1A)
D71  A 901 (-3.9A)
0.84A25.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3h3b RECEPTOR
TYROSINE-PROTEIN
KINASE ERBB-2
(Homo
sapiens)		4 / 8LEU A 118
VAL A  80
ILE A  55
TYR A  28
None
0.92A19.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3ibj CGMP-DEPENDENT
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		4 / 8LEU A 623
VAL A 646
PHE A 746
MET A 757
None
0.93A21.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3ibj CGMP-DEPENDENT
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		5 / 8LEU A 770
ILE A 826
TYR A 827
GLN A 859
PHE A 862
None
0.78A21.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3lrh ANTI-HUNTINGTIN VL
DOMAIN
(Homo
sapiens)		4 / 8LEU A  40
VAL A 109
ILE A  76
PHE A  63
None
0.97A14.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3o57 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		4 / 8ILE A 410
PHE A 414
GLN A 443
PHE A 446
ZG2  A 506 (-4.4A)
ZG2  A 506 (-4.4A)
ZG2  A 506 (-3.3A)
ZG2  A 506 (-3.6A)
0.47A27.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3qnw CASPASE-6
(Homo
sapiens)		4 / 8LEU B 232
VAL A 115
ILE A  49
PHE A  78
None
0.98A15.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		4 / 8ILE A 336
MET A 357
GLN A 369
PHE A 372
ILE  A 336 ( 0.4A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.86A27.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		4 / 8ILE A 336
PHE A 340
GLN A 369
PHE A 372
ILE  A 336 ( 0.4A)
PHE  A 340 (-1.3A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.54A27.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3ui7 CAMP AND
CAMP-INHIBITED CGMP
3',5'-CYCLIC
PHOSPHODIESTERASE
10A
(Homo
sapiens)		8 / 8LEU A 635
VAL A 678
ILE A 692
TYR A 693
PHE A 696
MET A 713
GLN A 726
PHE A 729
None
C1L  A   1 (-4.9A)
C1L  A   1 (-4.3A)
None
C1L  A   1 ( 4.7A)
C1L  A   1 (-3.7A)
C1L  A   1 (-2.9A)
C1L  A   1 (-3.5A)
0.45A100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		3zl4 A17 ANTIBODY FAB
FRAGMENT LAMBDA
LIGHT CHAIN
(Homo
sapiens)		4 / 8LEU L  40
VAL L 108
ILE L  76
PHE L  63
None
0.95A18.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4e93 TYROSINE-PROTEIN
KINASE FES/FPS
(Homo
sapiens)		4 / 8LEU A 684
ILE A 619
TYR A 614
PHE A 702
None
0.95A23.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4htz CGMP-DEPENDENT
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		4 / 8LEU A 623
VAL A 646
PHE A 746
MET A 757
None
0.89A35.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4htz CGMP-DEPENDENT
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		7 / 8LEU A 770
ILE A 826
TYR A 827
PHE A 830
MET A 847
GLN A 859
PHE A 862
None
0.68A35.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4hva CASPASE-6
(Homo
sapiens)		4 / 8LEU A 232
VAL A 115
ILE A  49
PHE A  78
None
0.95A21.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4ig9 NAD-DEPENDENT
PROTEIN DEACETYLASE
SIRTUIN-1
(Homo
sapiens)		4 / 8LEU A 493
VAL A 258
ILE A 464
PHE A 329
None
0.94A25.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4kwg ALDEHYDE
DEHYDROGENASE,
MITOCHONDRIAL
(Homo
sapiens)		4 / 8LEU A 129
VAL A 218
TYR A 485
GLN A 164
None
0.64A19.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4phc HISTIDINE--TRNA
LIGASE, CYTOPLASMIC
(Homo
sapiens)		4 / 8LEU A 241
ILE A 234
PHE A 221
MET A 220
None
0.98A20.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4rwf MALTOSE TRANSPORTER
SUBUNIT, RECEPTOR
ACTIVITY-MODIFYING
PROTEIN 2,
CALCITONIN
GENE-RELATED PEPTIDE
TYPE 1 RECEPTOR
FUSION PROTEIN
(Escherichia
coli;
Homo
sapiens)		4 / 8LEU A 264
ILE A  62
TYR A  72
PHE A  69
None
0.99A18.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4v1d SINGLE CHAIN
ANTIBODY FRAGMENT
RU1, LIGHT CHAIN
(Homo
sapiens)		4 / 8LEU E 179
VAL E 248
ILE E 215
PHE E 202
None
0.89A17.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4wzi CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		4 / 8ILE A 582
PHE A 586
GLN A 615
PHE A 618
None
0.56A20.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4y5x DIABODY 310 VH
DOMAIN
(Homo
sapiens)		4 / 8LEU B  40
VAL B 109
ILE B  76
PHE B  63
None
None
None
PEG  B 201 (-4.7A)
0.97A15.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEY_B_EV1B1771_1
(CAMP AND
CAMP-INHIBITED CGMP
3', 5'-CYCLIC
PHOSPHODIESTERASE)		4zzh NAD-DEPENDENT
PROTEIN DEACETYLASE
SIRTUIN-1
(Homo
sapiens)		4 / 8LEU A 493
VAL A 258
ILE A 464
PHE A 329
None
0.93A22.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		1soj CGMP-INHIBITED
3',5'-CYCLIC
PHOSPHODIESTERASE B
(Homo
sapiens)		6 / 9TYR A 736
ILE A 955
PHE A 959
GLN A 988
PHE A 991
ILE A 995
IBM  A2111 (-4.5A)
IBM  A2111 (-4.2A)
None
IBM  A2111 (-3.3A)
IBM  A2111 (-3.6A)
None
0.58A31.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		1zkl HIGH-AFFINITY
CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 7A
(Homo
sapiens)		5 / 9TYR A 211
ASN A 365
PHE A 384
GLN A 413
PHE A 416
IBM  A 503 (-4.6A)
IBM  A 503 ( 4.7A)
IBM  A 503 (-4.5A)
IBM  A 503 (-3.0A)
IBM  A 503 (-3.4A)
0.53A33.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		2qyk CYCLIC AMP-SPECIFIC
PHOSPHODIESTERASE
HSPDE4A10
(Homo
sapiens)		8 / 9TYR A 371
ASN A 533
ILE A 548
PHE A 552
MET A 569
GLN A 581
PHE A 584
ILE A 588
NPV  A   3 (-4.4A)
NPV  A   3 (-4.4A)
NPV  A   3 (-3.8A)
NPV  A   3 (-4.8A)
NPV  A   3 (-3.1A)
NPV  A   3 (-3.1A)
NPV  A   3 (-3.3A)
None
0.34A82.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		2qyk CYCLIC AMP-SPECIFIC
PHOSPHODIESTERASE
HSPDE4A10
(Homo
sapiens)		8 / 9TYR A 371
MET A 485
ASN A 533
ILE A 548
PHE A 552
MET A 569
GLN A 581
PHE A 584
NPV  A   3 (-4.4A)
None
NPV  A   3 (-4.4A)
NPV  A   3 (-3.8A)
NPV  A   3 (-4.8A)
NPV  A   3 (-3.1A)
NPV  A   3 (-3.1A)
NPV  A   3 (-3.3A)
0.59A82.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		2qym PHOSPHODIESTERASE 4C
(Homo
sapiens)		5 / 9TYR A 281
ASN A 443
ILE A 458
PHE A 494
ILE A 498
None
0.65A82.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		2qym PHOSPHODIESTERASE 4C
(Homo
sapiens)		5 / 9TYR A 281
MET A 395
ASN A 443
ILE A 458
PHE A 494
None
0.67A82.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		3b2r CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		5 / 9TYR A 612
PHE A 786
GLN A 817
PHE A 820
ILE A 824
VDN  A   1 (-4.8A)
None
VDN  A   1 (-3.0A)
VDN  A   1 (-3.6A)
None
0.40A31.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		3bjc CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		5 / 9TYR A 612
PHE A 786
GLN A 817
PHE A 820
ILE A 824
None
WAN  A 901 (-4.8A)
WAN  A 901 (-3.1A)
WAN  A 901 (-3.7A)
None
0.42A17.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		3ecn HIGH AFFINITY
CAMP-SPECIFIC AND
IBMX-INSENSITIVE
3',5'-CYCLIC
PHOSPHODIESTERASE 8A
(Homo
sapiens)		5 / 9TYR A 555
ILE A 744
GLN A 778
PHE A 781
ILE A 786
None
IBM  A   3 (-4.3A)
IBM  A   3 (-3.4A)
IBM  A   3 (-3.5A)
None
1.45A33.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		3ecn HIGH AFFINITY
CAMP-SPECIFIC AND
IBMX-INSENSITIVE
3',5'-CYCLIC
PHOSPHODIESTERASE 8A
(Homo
sapiens)		6 / 9TYR A 555
MET A 670
ASN A 729
ILE A 744
GLN A 778
PHE A 781
None
IBM  A   3 (-4.5A)
None
IBM  A   3 (-4.3A)
IBM  A   3 (-3.4A)
IBM  A   3 (-3.5A)
0.53A33.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		3g4g CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		8 / 9TYR A 325
MET A 439
ASN A 487
ILE A 502
PHE A 506
GLN A 535
PHE A 538
ILE A 542
None
D71  A 901 ( 4.0A)
D71  A 901 (-4.5A)
D71  A 901 (-4.1A)
D71  A 901 (-4.8A)
D71  A 901 (-3.1A)
D71  A 901 (-3.9A)
None
0.44A81.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		3ibj CGMP-DEPENDENT
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		5 / 9TYR A 655
ILE A 826
GLN A 859
PHE A 862
ILE A 866
None
0.68A18.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		3o57 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		5 / 9ILE A 410
MET A 431
GLN A 443
PHE A 446
ILE A 450
ZG2  A 506 (-4.4A)
ZG2  A 506 (-3.4A)
ZG2  A 506 (-3.3A)
ZG2  A 506 (-3.6A)
None
0.81A82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		3o57 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		5 / 9MET A 347
ILE A 410
MET A 431
GLN A 443
PHE A 446
ZG2  A 506 (-3.9A)
ZG2  A 506 (-4.4A)
ZG2  A 506 (-3.4A)
ZG2  A 506 (-3.3A)
ZG2  A 506 (-3.6A)
0.95A82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		3o57 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		7 / 9TYR A 233
ASN A 395
ILE A 410
PHE A 414
GLN A 443
PHE A 446
ILE A 450
None
ZG2  A 506 (-4.3A)
ZG2  A 506 (-4.4A)
ZG2  A 506 (-4.4A)
ZG2  A 506 (-3.3A)
ZG2  A 506 (-3.6A)
None
0.52A82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		3o57 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		7 / 9TYR A 233
MET A 347
ASN A 395
ILE A 410
PHE A 414
GLN A 443
PHE A 446
None
ZG2  A 506 (-3.9A)
ZG2  A 506 (-4.3A)
ZG2  A 506 (-4.4A)
ZG2  A 506 (-4.4A)
ZG2  A 506 (-3.3A)
ZG2  A 506 (-3.6A)
0.77A82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		8 / 9TYR A 159
ASN A 321
ILE A 336
PHE A 340
MET A 357
GLN A 369
PHE A 372
ILE A 376
TYR  A 159 (-1.3A)
ASN  A 321 (-0.6A)
ILE  A 336 ( 0.4A)
PHE  A 340 (-1.3A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
ILE  A 376 (-0.6A)
0.53A94.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		3sl5 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		8 / 9TYR A 159
MET A 273
ASN A 321
ILE A 336
PHE A 340
MET A 357
GLN A 369
PHE A 372
TYR  A 159 (-1.3A)
MET  A 273 (-0.0A)
ASN  A 321 (-0.6A)
ILE  A 336 ( 0.4A)
PHE  A 340 (-1.3A)
MET  A 357 (-0.0A)
GLN  A 369 (-0.6A)
PHE  A 372 (-1.3A)
0.73A94.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		3ui7 CAMP AND
CAMP-INHIBITED CGMP
3',5'-CYCLIC
PHOSPHODIESTERASE
10A
(Homo
sapiens)		5 / 9TYR A 524
ILE A 692
MET A 713
GLN A 726
PHE A 729
C1L  A   1 ( 4.8A)
C1L  A   1 (-4.3A)
C1L  A   1 (-3.7A)
C1L  A   1 (-2.9A)
C1L  A   1 (-3.5A)
1.16A28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		3ui7 CAMP AND
CAMP-INHIBITED CGMP
3',5'-CYCLIC
PHOSPHODIESTERASE
10A
(Homo
sapiens)		5 / 9TYR A 524
ILE A 692
PHE A 696
GLN A 726
PHE A 729
C1L  A   1 ( 4.8A)
C1L  A   1 (-4.3A)
C1L  A   1 ( 4.7A)
C1L  A   1 (-2.9A)
C1L  A   1 (-3.5A)
0.74A28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		4htz CGMP-DEPENDENT
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		6 / 9TYR A 655
ILE A 826
PHE A 830
GLN A 859
PHE A 862
ILE A 866
None
0.43A28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		4htz CGMP-DEPENDENT
3',5'-CYCLIC
PHOSPHODIESTERASE
(Homo
sapiens)		6 / 9TYR A 655
ILE A 826
PHE A 830
MET A 847
PHE A 862
ILE A 866
None
0.85A28.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		4wzi CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		8 / 9TYR A 405
MET A 519
ASN A 567
ILE A 582
PHE A 586
GLN A 615
PHE A 618
ILE A 622
None
0.56A48.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		5b25 CALCIUM/CALMODULIN-D
EPENDENT
3',5'-CYCLIC
NUCLEOTIDE
PHOSPHODIESTERASE 1B
(Homo
sapiens)		6 / 9TYR A 222
MET A 336
PHE A 392
GLN A 421
PHE A 424
ILE A 428
None
4QJ  A 603 ( 3.9A)
GOL  A 607 (-3.9A)
4QJ  A 603 (-3.0A)
4QJ  A 603 (-3.5A)
None
0.75A38.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		5ohj CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		7 / 9MET A 519
ASN A 567
ILE A 582
PHE A 586
MET A 603
GLN A 615
PHE A 618
9VE  A 801 (-3.8A)
9VE  A 801 (-4.1A)
9VE  A 801 (-4.1A)
9VE  A 801 (-3.6A)
9VE  A 801 (-3.6A)
9VE  A 801 (-3.2A)
9VE  A 801 (-3.9A)
0.92A11.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		5ohj CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B
(Homo
sapiens)		8 / 9TYR A 405
ASN A 567
ILE A 582
PHE A 586
MET A 603
GLN A 615
PHE A 618
ILE A 622
None
9VE  A 801 (-4.1A)
9VE  A 801 (-4.1A)
9VE  A 801 (-3.6A)
9VE  A 801 (-3.6A)
9VE  A 801 (-3.2A)
9VE  A 801 (-3.9A)
9VE  A 801 (-4.8A)
0.63A11.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		5wh6 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		8 / 9TYR A 159
ASN A 321
ILE A 336
PHE A 340
MET A 357
GLN A 369
PHE A 372
ILE A 376
AKJ  A 601 ( 4.7A)
AKJ  A 601 (-4.3A)
AKJ  A 601 (-3.8A)
AKJ  A 601 (-4.5A)
AKJ  A 601 (-3.4A)
AKJ  A 601 (-3.0A)
AKJ  A 601 (-4.1A)
None
0.30Aundetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IAK_A_EV1A415_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D)		5wh6 CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4D
(Homo
sapiens)		8 / 9TYR A 159
MET A 273
ASN A 321
ILE A 336
PHE A 340
MET A 357
GLN A 369
PHE A 372
AKJ  A 601 ( 4.7A)
AKJ  A 601 ( 3.9A)
AKJ  A 601 (-4.3A)
AKJ  A 601 (-3.8A)
AKJ  A 601 (-4.5A)
AKJ  A 601 (-3.4A)
AKJ  A 601 (-3.0A)
AKJ  A 601 (-4.1A)
0.52Aundetectable